血液スクリーニングの市場規模、シェア、成長分析、製品別、技術別、エンドユーザー別、地域別 - 産業予測 2025-2032年

血液スクリーニング市場規模は2023年に25億米ドルと評価され、予測期間（2025-2032年）のCAGRは8.7%で、2024年の27億2,000万米ドルから2032年には53億米ドルに成長する見通しです。

安全な血液に対する世界の需要とスクリーニング技術の進歩が、血液スクリーニング市場の将来を形成しています。世界中で献血率が上昇するにつれ、ドナーの安全性を確保するために包括的なスクリーニング手順の必要性が不可欠となっています。この動向は、優れたインフラストラクチャーと国民の意識が献血の増加を後押ししている、政府による採血イニシアチブの強力な支援がある国々で特に顕著です。最近の献血の急増は、感染症を検出するための高度な検査方法の必要性を浮き彫りにし、それによってレシピエントの安全を守っています。HIV、B型肝炎、C型肝炎、ジカウイルスなどの感染症に対する公衆衛生上の懸念は、洗練されたスクリーニング技術を採用することの重要性をさらに強調しています。その結果、化学発光免疫測定法（CLIA）や核酸増幅検査（NAT）のような技術は、世界中の血液スクリーニング施設で標準となりつつあります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 特許分析
• 規制分析
• 技術分析
• ケーススタディ

血液スクリーニング市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 試薬とキット
  • 天然試薬とキット
  • エリサ試薬とキット
  • その他の試薬とキット
• 機器
  • レンタル購入
  • 完全購入
• ソフトウェアとサービス

血液スクリーニング市場規模：技術別& CAGR（2025-2032）

• 市場概要
• 核酸検査（NAT）
  • 転写介在増幅（TMA）
  • リアルタイムポリメラーゼ連鎖反応（RT-PCR）
• 血清学/免疫測定
  • 化学発光免疫測定（CLIA）
  • 蛍光免疫測定（FIA）
  • 比色免疫測定法/ELISA（CI/ELISA）
• 迅速検査
• ウェスタンブロットアッセイ
• 次世代シーケンシング（NGS）

血液スクリーニング市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 血液バンク
• 病院

血液スクリーニング市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Abbott Laboratories（USA）
• Becton, Dickinson and Company（USA）
• Bio-Rad Laboratories, Inc.（USA）
• bioMerieux SA（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Grifols, S.A.（Spain）
• Hologic, Inc.（USA）
• Quotient Limited（UK）
• Siemens Healthineers AG（Germany）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific Inc.（USA）
• Danaher Corporation（USA）
• Grifols Diagnostic Solutions Inc.（USA）
• Haemonetics Corporation（USA）
• Natera, Inc.（USA）
• Novartis International AG（Switzerland）
• Promega Corporation（USA）

結論と提言

Blood Screening Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 5.3 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global demand for safe blood, coupled with advancements in screening technologies, is shaping the future of the blood screening market. As blood donation rates rise worldwide, the need for comprehensive screening procedures becomes essential to ensure donor safety. This trend is particularly prevalent in countries with robust government support for blood collection initiatives, where superior infrastructure and public awareness drive increased contributions. Recent surges in blood donations highlight the necessity for advanced testing methods to detect infections, thereby safeguarding recipients. Public health concerns over infectious diseases like HIV, hepatitis B and C, and Zika virus further emphasize the importance of adopting refined screening techniques. Consequently, technologies such as chemiluminescence immunoassays (CLIA) and nucleic acid amplification tests (NAT) are becoming standard in blood screening facilities globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Blood Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Blood Screening Market Segments Analysis

Global Blood Screening Market is segmented by Product, Technology, End User and region. Based on Product, the market is segmented into Reagents & Kits, Instruments and Software & Services. Based on Technology, the market is segmented into Nucleic Acid Tests (NAT), Serology/Immunoassays, Rapid Tests, Western Blot Assays and Next-Generation Sequencing (NGS). Based on End User, the market is segmented into Blood Banks and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Blood Screening Market

The blood screening market is primarily driven by advancements in the understanding and response to infectious diseases, particularly the surge in bacterial and viral infections. There is a marked increase in the utilization of blood tests among healthcare professionals, fueled by evolving public health priorities aimed at monitoring disease outbreaks and guaranteeing the safety of blood transfusions. This trend reflects a heightened awareness of blood-borne infections and the critical need for early detection, prompting hospitals and clinics to invest in cutting-edge blood screening technologies. As a result, the market is poised for continued growth in the coming years, spurred by an emphasis on safety and preventive healthcare measures.

Restraints in the Blood Screening Market

A significant barrier to the blood screening market is the high cost associated with advanced screening tools and technologies. Many healthcare facilities, particularly in developing regions, find it challenging to afford the expensive blood screening equipment necessary for thorough testing. This financial constraint restricts their ability to implement comprehensive testing protocols, ultimately hindering market growth. The high costs not only limit the initial acquisition of the technology but also pose ongoing maintenance and operational expenses, further complicating the situation for healthcare providers and preventing them from keeping pace with advancements in blood screening practices.

Market Trends of the Blood Screening Market

The blood screening market is experiencing a significant shift towards point-of-care (POC) testing, driven by the need for rapid and decentralized diagnostics in healthcare settings. This trend enhances the delivery of near-instant results for essential laboratory tests, eliminating the delays associated with traditional sample processing at centralized labs. POC testing is increasingly being integrated into emergency rooms, outpatient clinics, and other medical facilities, facilitating quicker clinical decisions and improving patient experiences. As technological advancements continue to diversify POC blood screening options, the market is poised for robust growth, reflecting an increasing emphasis on efficiency and quality care in healthcare delivery.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global Blood Screening Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Reagents & Kits
  • Nat Reagents & Kits
  • Elisa Reagents & Kits
  • Other Reagents & Kits
• Instruments
  • Rental Purchase
  • Outright Purchase
• Software & Services

Global Blood Screening Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Nucleic Acid Tests (NAT)
  • Transcription-Mediated Amplification (TMA)
  • Real-Time Polymerase Chain Reaction (RT-PCR)
• Serology/Immunoassays
  • Chemiluminescent Immunoassays (CLIA)
  • Fluorescent Immunoassays (FIA)
  • Colorimetric Immunoassays/ELISA (CI/ELISA)
• Rapid Tests
• Western Blot Assays
• Next-Generation Sequencing (NGS)

Global Blood Screening Market Size by End User & CAGR (2025-2032)

• Market Overview
• Blood Banks
• Hospitals

Global Blood Screening Market Size & CAGR (2025-2032)

• North America (Product & Service, Technology, End User)
  • US
  • Canada
• Europe (Product & Service, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quotient Limited (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols Diagnostic Solutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations